{"id":30250,"date":"2025-03-25T00:00:01","date_gmt":"2025-03-24T16:00:01","guid":{"rendered":"https:\/\/flcube.com\/?p=30250"},"modified":"2025-03-25T00:00:02","modified_gmt":"2025-03-24T16:00:02","slug":"cansino-biologics-partners-with-grand-life-sciences-to-commercialize-tetanus-vaccine-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30250","title":{"rendered":"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China"},"content":{"rendered":"\n<p>Chinese firms CanSino Biologics Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/6185:HKG\">HKG: 6185<\/a>) and Grand Life Sciences have entered into an agreement to commercialize CanSino&#8217;s adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.<\/p>\n\n\n\n<p><strong>Vaccine Details and Regulatory Status<\/strong><br>The vaccine, which is fermented using a non-animal-source culture medium and is intended for the prevention of non-neonatal tetanus, is currently awaiting regulatory decisions in China. This innovative approach to vaccine production highlights CanSino&#8217;s commitment to advancing vaccine technology and addressing public health needs.<\/p>\n\n\n\n<p><strong>Strategic Partnership Benefits<\/strong><br>This partnership leverages Grand Life Sciences&#8217; expertise in market promotion and CanSino Biologics&#8217; research and development capabilities. By combining these strengths, the companies aim to expedite the vaccine&#8217;s market entry and ensure its effective distribution across Greater China, contributing to improved public health outcomes in the region.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":30251,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[466,1833,884,12],"class_list":["post-30250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cansino-biologics","tag-grand-life-sciences","tag-hkg-6185","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino&#039;s adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30250\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China\" \/>\n<meta property=\"og:description\" content=\"Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino&#039;s adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30250\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T16:00:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T16:00:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2413-1-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China\",\"datePublished\":\"2025-03-24T16:00:01+00:00\",\"dateModified\":\"2025-03-24T16:00:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250\"},\"wordCount\":204,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2413-1-png.webp\",\"keywords\":[\"CanSino Biologics\",\"Grand Life Sciences\",\"HKG: 6185\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30250#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30250\",\"name\":\"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2413-1-png.webp\",\"datePublished\":\"2025-03-24T16:00:01+00:00\",\"dateModified\":\"2025-03-24T16:00:02+00:00\",\"description\":\"Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino's adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30250\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2413-1-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2413-1-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30250#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino's adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30250","og_locale":"en_US","og_type":"article","og_title":"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China","og_description":"Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino's adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.","og_url":"https:\/\/flcube.com\/?p=30250","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-24T16:00:01+00:00","article_modified_time":"2025-03-24T16:00:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2413-1-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30250#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30250"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China","datePublished":"2025-03-24T16:00:01+00:00","dateModified":"2025-03-24T16:00:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30250"},"wordCount":204,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30250#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2413-1-png.webp","keywords":["CanSino Biologics","Grand Life Sciences","HKG: 6185","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30250#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30250","url":"https:\/\/flcube.com\/?p=30250","name":"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30250#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30250#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2413-1-png.webp","datePublished":"2025-03-24T16:00:01+00:00","dateModified":"2025-03-24T16:00:02+00:00","description":"Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino's adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30250#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30250"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30250#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2413-1-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2413-1-png.webp","width":1080,"height":608,"caption":"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30250#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2413-1-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30250"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30250\/revisions"}],"predecessor-version":[{"id":30252,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30250\/revisions\/30252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30251"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}